Irkkan Cigdem, Balci Serdar, Güler Tezel Gaye, Akinci Bülent, Yalcin Bülent, Güler Gülnur
*Department of Pathology, Ankara Ataturk Research and Training Hospital ‡Department of Pathology ∥Department of Medical Oncology, Yildirim Beyazit University, Ankara Ataturk Research and Training Hospital †Department of Pathology, Ankara Oncology Research and Training Hospital §Department of Pathology, Hacettepe University, Ankara, Turkey.
Appl Immunohistochem Mol Morphol. 2017 Oct;25(9):609-614. doi: 10.1097/PAI.0000000000000353.
Gastric carcinomas are highly mortal neoplasms for which new therapeutic options are being searched. The molecular subtyping of gastric adenocarcinomas was proposed recently, and the relationship between etiopathogenetic types is still under investigation. Here we compared histopathologic, prognostic, and survival differences between Epstein-Barr virus (EBV)-positive and Her2-positive gastric adenocarcinomas. In a retrospective design, we searched the EBV status with Epstein Barr Virus encoded small RNA (EBER) in situ hybridization, and the Her2 status both by immunohistochemistry and by chromogenic in situ hybridization of 106 gastrectomized gastric carcinomas. Histologic and clinical prognostic parameters and survival information were determined, and retrieved from archival tissues and clinical notes. The Her2 positivity rate was 12.3% and the EBV positivity rate was 7.6%. Among EBER-positive cases, Her2 positivity was not detected. Her2 positivity was detected more in intestinal differentiated tumors, whereas EBER positivity was detected in undifferentiated tumors (P=0.003). There was no correlation of Her2 or EBER positivity with the tumor stage. Median survivals of EBER-positive, Her2-positive, and both negative cases were 11.5, 18, and 20.5 months, respectively. The tumor stage and distant metastasis were found to be significant for survival in the multivariate analysis. In our 106 gastrectomized gastric carcinoma cases, EBV-positive and Her2-positive groups were found to be unrelated as proposed in the upcoming classification of gastric carcinomas.
胃癌是死亡率很高的肿瘤，目前正在寻找新的治疗方法。胃腺癌的分子亚型分类是最近提出的，其病因发病类型之间的关系仍在研究中。在此，我们比较了爱泼斯坦-巴尔病毒（EBV）阳性和人表皮生长因子受体2（Her2）阳性胃腺癌之间的组织病理学、预后和生存差异。采用回顾性设计，我们通过爱泼斯坦-巴尔病毒编码小RNA（EBER）原位杂交检测106例接受胃切除术的胃癌患者的EBV状态，同时通过免疫组织化学和显色原位杂交检测Her2状态。确定组织学和临床预后参数以及生存信息，并从存档组织和临床记录中获取。Her2阳性率为12.3%，EBV阳性率为7.6%。在EBER阳性病例中，未检测到Her2阳性。Her2阳性在肠化生肿瘤中检测到的更多，而EBER阳性在未分化肿瘤中检测到（P=0.003）。Her2或EBER阳性与肿瘤分期无相关性。EBER阳性、Her2阳性和两者均阴性病例的中位生存期分别为11.5个月、18个月和20.5个月。在多变量分析中，发现肿瘤分期和远处转移对生存有显著影响。在我们的106例接受胃切除术的胃癌病例中，EBV阳性和Her2阳性组与即将出台的胃癌分类中提出的情况无关。
